Fig. 3: Subconjunctival injection of sunitinib MPs suppresses type 2 choroidal NV.
From: Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles
C57BL/6 mice received a 2 µl subconjunctival injection of microparticles (MP) containing 20 or 2 µg of sunitinib (Suni) or empty MP in one eye and no injection in the fellow eye. At 1 week after injection, Bruch’s membrane was ruptured by laser photocoagulation at three locations in each eye. One week after laser, mice were euthanized and choroidal flat mounts were stained with FITC-labeled GSA lectin and the area of choroidal neovascularization (CNV) was measured at Bruch’s membrane rupture sites by an investigator masked with regard to treatment. The three values from each eye were averaged to give a single experimental value. The mean (±SEM) area of CNV was significantly less in eyes injected with MP containing 20 µg (a) or 2 µg (b) sunitinib vs. those injected with empty MP, but there was no significant difference between fellow eyes for each group. *p < 0.05 for difference from all other groups by Kruskal Wallis test followed by Dunn’s test. Bar = 100 µm. Source data are provided as a Source Data file.
